Significance of Low Plasma Levels of Brain-Derived Neurotrophic Factor in Patients With Heart Failure

Seiji Takashio(Kumamoto University), Hisao Ogawa(Kumamoto University Hospital), Yasuo Sugano(keiyu Hospital), Satoshi Yasuda(Tohoku University), Naoto Minamino(National Cerebral and Cardiovascular Center), Toshihisa Anzai(Hokkaido University), Seiji Hokimoto(Kumamoto University), Seigo Sugiyama(Diabetes Care Center), Megumi Yamamuro(IRYO Sosei University), Tomohiro Hayashi(National Cerebral and Cardiovascular Center), Yasuhiro Izumiya(Kumamoto University), Hiroyuki Takahama(National Cerebral and Cardiovascular Center)
The American Journal of Cardiology
April 18, 2015
10.1016/j.amjcard.2015.04.018
Cited by 70

Related Papers

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
|The Lancet|2017|1.3k
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
|The Lancet|2017|881
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
|New England Journal of Medicine|2011|753
<i>Bacteroides vulgatus</i> and <i>Bacteroides dorei</i> Reduce Gut Microbial Lipopolysaccharide Production and Inhibit Atherosclerosis
|Circulation|2018|618